Sponsored by:

Nuclear Medicine: Page 27

FDG-PET/CT scans assessed for clinical utility in COVID-19
By Will Morton
Monday, November 29 | 9:30 a.m.-10:30 a.m. | SSNMMI03-4 | Room S402In this talk, researchers will present a study to determine imaging findings and the potential clinical utility of FDG-PET/CT in patients with laboratory-confirmed COVID-19. They suggest FDG-PET/CT scans could be helpful in predicting disease severity.
November 22, 2021
Combining radiomics, AI with PET/MRI helps assess nodal status
By Amerigo Allegretto
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-3 | Room N226Here, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.
November 22, 2021
PET/MRI shows prowess for nodal staging in breast cancer
By Amerigo Allegretto
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-4 | Room N226In this presentation, researchers will compare nodal staging between CT, MRI, and FDG-PET/MRI in patients with newly diagnosed breast cancer.
November 22, 2021
Is FDG uptake normal in patients after ascending aorta replacement?
By Will Morton
Prerecorded, available throughout meeting | SPR-NMMI-16In this presentation, Dutch cardiovascular imaging specialists will discuss interpreting normal F-18 FDG uptake on PET/CT after patients undergo combined aortic valve and ascending aorta replacement.
November 22, 2021
New radiotracer promising for diagnosing infection in vivo
By Will Morton
Prerecorded, available throughout meeting | SPR-NMMI-14In this session exploring new frontiers in PET radiopharmaceuticals, researchers from the University of California, San Francisco will present results from an ongoing trial of a new carbon-11-labeled radiotracer that targets bacterial infection.
November 22, 2021
PET tracer synthesized for imaging cholesterol metabolism
By Will Morton
Thursday, December 2 | 1:30 p.m.-2:30 p.m. | SSNMMI08-1 | Room N228In this presentation, researchers will report a breakthrough after 40 years in the development of a new PET radiotracer for imaging abnormal cholesterol metabolism due to high levels of adrenal aldosterone.
November 22, 2021
PET/MRI assesses ankylosing spondylitis treatment
By Will Morton
Thursday, December 2 | 9:30 a.m.-10:00 a.m. | SSNMMI07-4 | Room E450BF-18 sodium fluoride PET/MR imaging of osteoblastic activity in ankylosing spondylitis patients can assess the effects of anti-tumor necrosis factor therapy, according to German researchers presenting in this session.
November 22, 2021
Antioxidant agent shows promise in reducing DNA damage from radiation
By Will Morton
Tuesday, November 30 | 9:30 a.m.-10:30 a.m. | SSNMMI05-2 | Room E353CIn this session on advances in radionuclide therapy, researchers will present work on the identification and development of an antioxidant agent that may reduce damage to DNA caused by ionizing radiation.
November 22, 2021
PET/CT classifies subtypes in progressive nuclear palsy
By Will Morton
Monday, November 29 | 3:00 p.m.-4:00 p.m. | SSNMMI04-4 | Room S405In this session on brain imaging, researchers from India will present a study that elucidates patterns of characteristic hypometabolism on F-18 FDG PET/CT in various subtypes of progressive nuclear palsy and their correlation with core clinical features.
November 22, 2021
Is PET radiotracer uptake in lymph nodes after COVID-19 vaccination associated with age?
By Will Morton
Monday, November 29 | 9:30 a.m.-10:30 a.m. | SSNMMI03-6 | Room S402Israeli researchers will offer findings in this presentation on PET/CT uptake in the deltoid muscle and axillary lymph nodes in patients who received COVID-19 mRNA-based vaccines. The group explored whether uptake is associated with patient age and immune status.
November 22, 2021
PET with F-18 fluoroestradiol tracer evaluated in women with breast cancer
By Will Morton
Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-2 | Room N226In this talk, researchers will discuss results of the first prospective study evaluating the performance of F-18 fluoroestradiol PET/CT in women with invasive lobular carcinoma breast cancer.
November 22, 2021
2017 11 07 18 37 9362 Roadies Ribbon 400
Ultrafast low-dose PET/CT equivalent to conventional imaging for cancer
By Will Morton
Sunday, November 28 | 2:30 p.m.-3:30 p.m. | SSNMMI02-2 | Room N226In this session covering technical advances in molecular imaging, researchers will present findings of a prospective phase III trial comparing an ultrafast, low-dose, whole-body FDG-PET/CT approach with conventional imaging in patients with cancer.
November 22, 2021
Previous Page
Page 27 of 438
Next Page